After Surging 298%, Is Nebius Stock Still a Buy? Here's What History Says.

Nebius’ Q1 revenue jumped 684% YoY to $399M (AI-cloud revenue up 841% to $390M), but sustaining its 2026 guidance of $3.0B–$3.4B will require roughly $934M of revenue per quarter over the last three quarters to reach the $3.2B midpoint. The stock has surged ~298% over the past year yet fell ~26% from its June record, and prior optimism around Meta/financing was quickly pressured after it raised about $4.34B via convertible notes. With shares trading at ~17x the 2026 revenue midpoint, investors are likely to focus on execution—capacity ramp timing and whether additional borrowing or dilution is needed.

Analysis

NBIS has moved from a story-stock regime to a throughput-and-funding regime. That usually compresses multiples before it improves them, because the market stops capitalizing backlog and starts discounting the probability-weighted cost of turning backlog into billable capacity. The key variable is no longer demand; it is whether power, racks, and GPUs arrive fast enough to avoid revenue recognition lag and another financing round.

The clearest beneficiaries are the picks-and-shovels names that monetize capex regardless of Nebius’ equity outcome: NVDA on accelerator demand, and potentially power/cooling/networking vendors in the broader AI infrastructure chain. By contrast, Nebius’ direct competitors in AI cloud and managed capacity can benefit if customers seek second-source availability when build schedules slip; the real competitive risk is customer churn to better-capitalized peers with faster delivery, not loss of headline contracts.

Near term, the stock is trading like a financing event risk rather than a growth compounder. Over the next 1-3 months, the catalyst path is earnings plus construction updates; any hint that the third-quarter capacity ramp slips or that funding is becoming more equity-heavy should pressure the shares hard. Over 6-18 months, the thesis only stabilizes if management proves non-dilutive financing and sustained sequential revenue ramps; otherwise the equity remains a leveraged claim on a very expensive buildout.

Contrarianly, the market may be over-focused on dilution and under-focused on the value of contracted AI capacity in a supply-constrained industry. If Nebius can fund projects at the asset level and keep equity issuance limited, the current de-rating may prove too aggressive. But absent that proof, this is still a "show me" name, not a buy-the-backlog name.

Key Decisions for Investors

• Avoid chasing NBIS strength into the next earnings print; if already long, trim ahead of the capacity/update window and require proof of revenue inflection before re-adding.
• For event-driven downside exposure, use NBIS put spreads 1-3 months out rather than naked short equity; the cleanest catalyst is a miss on capacity timing or a larger-than-expected financing package.
• Pair trade: long NVDA / short NBIS as a hedge against AI infra execution risk. NVDA monetizes the buildout regardless of which operator wins; NBIS carries the schedule and dilution risk.
• Watch for a financing disclosure or revised capex plan as the falsifier. If management funds expansion mostly with project debt or customer prepayments and does not re-issue equity, the short thesis weakens materially.
• If NBIS can sustain a post-earnings revenue run-rate above the implied quarterly hurdle and confirm third-quarter capacity online, cover tactical shorts quickly; the squeeze risk is high in a crowded AI infrastructure tape.